IDRA - Idera Pharmaceuticals completes acquisition of Aceragen

• Idera Pharmaceuticals ( NASDAQ: IDRA ) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction.
• The acquisition, not subject to the approval of Idera stockholders, was unanimously approved by the board of both the companies.
• The combined cash of the two companies is expected help in funding the advancement of Aceragen's pipeline through 2023.
• Idera's former CEO, Vincent Milano, has been named board chair.
• Aceragen's former CEO, John Taylor, succeeds Milano.
• Additionally, Aceragen's former chief medical officer, Carl Kraus, will serve in that role for Idera.
• Also, Aceragen's former COO, Daniel Salain, will serve in that role for Idera.
• And, Andy Jordan, Aceragen's former CFO has been appointed chief strategy officer for Idera.
• IDRA shares were trading +19.85% post-market.
• Source: Press Release

For further details see: